Welcome! All participants will be muted during the presentation and discussion. Please use the chat for questions.

During the Q&A, please unmute for a question or comment, and mute if you are not speaking. Thank you!
Webinar Agenda

1) Welcome & Introductions
2) MPT R&D Pipeline Snapshots
3) Moderated Discussion
4) Q&A
5) Wrap Up & Adjourn
Multipurpose Prevention Technologies

**MPTs combine protection against:**
- Unintended pregnancy
- HIV
- Other STIs

**MPTs have the potential to:**
- Address overlapping risks
- Synergize prevention approaches
- Increase motivation for adherence
- Destigmatize HIV prevention
- Improve health & economic outcomes
MPTs in the R&D Pipeline

MPTs by Delivery Type (n=24)*

* As of February 2021

Intravaginal rings (vaginal & rectal) - 10
Gels - 4
Fast dissolving inserts - 2
Films - 1
Implants - 1
Microarray Patches - 1
Oral tablets - 1

Learn more at MPTs101.org
Building Upon Agency Support for Socio-behavioral Research

Utilizing Behavioral, Social, and Marketing Research to Advance Contraceptive Development Workshop (NICHD – 11-25 Sep 2020)

Biomedical HIV Prevention Product Investment Framework (USAID, IMPT – Sep 2019)
Our Discussants

Deborah Anderson  
Boston University  
School of Medicine

Mary Weitzel  
Yaso Therapeutics

Matthew Quaife  
London School of Hygiene  
& Tropical Medicine

Betsy Tolley  
FHI 360

Khatija Ahmed  
Setshaba Research Centre

Joseph Murungu  
Pangaea Zimbabwe  
AIDS Trust

Let’s Talk MPTs Discussion Series  
25 February 2021
MPT Pipeline Snapshots: From the lab to the hands of women

- Deborah Anderson – Boston University School of Medicine

- Mary Weitzel – Yaso Therapeutics
Monoclonal antibody-based MPTs for protection against STIs and contraception

- Natural products
- New cost effective production platforms
- Over 100 mAbs approved for clinical use
- Infinite variety, combinations
Development of MAb MPTs

1. MB66: anti-HIV (VRC01) and HSV (HSV8) mAbs
2. ZB-06: antisperm antibody (HCA)
3. Next Generation: anti-HIV (multiple), HSV and sperm

In Vitro Studies
Animal Challenge
QA Stability Testing
RVI Rat TCR
Safety Acceptability
Ex Vivo Efficacy
Collaborators and Acknowledgements

**Boston University School of Medicine**
Deborah Anderson, PhD
Joseph Politch, PhD

**Johns Hopkins University**
Richard Cone, Ph.D.
Thomas Moench, M.D.

**University of North Carolina**
Samuel Lai, Ph.D.

**Yerkes Primate Center**
Francois Villinger, D.V.M., Ph.D.

**Brown University**
Susan CuUvin, M.D.
Kate Guthrie, Ph.D.

**Harvard Medical School**
Kenneth Mayer, M.D.

**Eastern Virginia Medical School**
Andrea Thurman, M.D.

**MappBio/ZabBio**
Kevin Whaley, Ph.D.
Larry Zeitlin, Ph.D.
Miles Brennan, Ph.D.

**Oak Crest Institute**
Marc Baum, Ph.D.
John Moss, Ph.D.

**Aridis Pharmaceuticals**

**Kentucky Bioprocessing**

**Mucommune**
Richard Cone, Ph.D.
Thomas Moench, M.D.
Samuel Lai, Ph.D.

**NIH-NIAID**
Jim Turpin, Ph.D.  [IPCP Grant U19 AI096398]

**NIH-NICHD**
Dan Johnston, Ph.D.  [CRC Grant P50 HD096957]

**Gates Foundation**
MPT Pipeline Snapshots: From the lab to the hands of women

• Deborah Anderson – Boston University School of Medicine

• Mary Weitzel – Yaso Therapeutics

Let’s Talk MPTs Discussion Series
25 February 2021
Let’s talk MPTS
Integrating socio-behavioral research into R&D

Mary Weitzel - President CEO
February 25, 2021

NICHD R44 HD092206
Yaso snapshot

**Snapshot**

- Management team with 100+ years of development and commercialization experience in contraceptives, women’s consumer and health products
- Partnering with world-class CROs, academics and subject-matter experts
- Target IND submission Q2 2021
- Patent protection in USA, EU, China, Canada and Mexico

**Track Record**

- $6.5 MM non-dilutive funding from NIH to support development through 5/2021
- 6 awarded grants from NIH
- 1st prize - Harvard Business School Alumni New Venture competition
- Drug developed from benchtop to pre-IND in 6 years
Solution - what women want

Yaso Gel

Contraceptive + STI prevention + Herpes Treatment.

· Non-hormonal
· Pleasant gel used during sexual intercourse
· Effective and safe
· Affordable
· Dosage form alternatives
  ▪ Prefilled applicator
  ▪ Bottled gel
  ▪ Fast-dissolving vaginal film
PPCM blocks pathogen attachment and renders sperm infertile

Herpes simplex G-B2 attaches to heparan sulfate

PPCM (gold) binds G-B2 attachment sites, preventing infection

Acrosome loss = loss of fertility
IC50 = 10 µg/mL
Our Discussion Topics

• Socio-behavioral approaches & challenges
• Acquiring input from diverse populations
• Clinical trial design
• Understanding the MPT market landscape
Our Discussion Topics

- Socio-behavioral approaches & challenges
- **Acquiring input from diverse populations**
- Clinical trial design
- Understanding the MPT market landscape
Our Discussion Topics

- Socio-behavioral approaches & challenges
- Acquiring input from diverse populations
- Clinical trial design
- Understanding the MPT market landscape
Our Discussion Topics

- Socio-behavioral approaches & challenges
- Acquiring input from diverse populations
- Clinical trial design
- Understanding the MPT market landscape
Q&A

All

- Please unmute for questions or comments.
- Please announce your name and affiliation when speaking.
Other Items & Wrap Up
MPTs have the potential to usher in a reproductive revolution by bridging issues that benefit society, invigorate economies, and improve the health of women, families, and our planet.
Like. Follow. Connect.

We’re on social media!

@Initiative4MPTs

#IMPTnetwork #WithanMPTIcan #MPTs4SRH
Thank You!

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the Initiative for MPTs (IMPT), CAMI Health, the Public Health Institute (PHI), and its partners and do not necessarily reflect the views of USAID or the U.S. Government. The IMPT is a project of CAMI Health, an organization dedicated to women’s reproductive health and empowerment, housed at PHI.